{"entity":{"id":"nct07280832","kind":"trial","name":"Phase I/II Clinical Study of JMT108 Injection for the Treatment of Advanced Malignant Melanoma and Urinary Tract Tumors","aka":[],"tldr":"A phase 1/2 trial of JMT108 in melanoma, run by Shanghai JMT-Bio Inc., now recruiting.","summary":"Phase I/II Clinical Study of JMT108 Injection for the Treatment of Advanced Malignant Melanoma and Urinary Tract Tumors is a phase 1/2 interventional study registered as NCT07280832 by Shanghai JMT-Bio Inc., with 500 participants planned, started 2025-12-17 and due to reach its primary completion in 2026-11-30. Interventions recorded: JMT108.","status":"recruiting","asOf":"2026-09-16","links":[{"label":"ClinicalTrials.gov NCT07280832","url":"https://clinicaltrials.gov/study/NCT07280832"}],"tags":["pipeline","ctgov-ingest"],"related":[],"cancers":["melanoma"],"sections":[],"technologies":[],"targets":[],"drugs":[],"companies":["cspc"],"institutions":[],"pathways":[],"terms":[],"trials":[],"people":[],"bottlenecks":[],"keyPapers":[],"journals":[],"notes":[],"nct":"NCT07280832","phase":"1/2","setting":"Open-Label, Multicenter Phase I/II Study to Evaluate the Safety, Tolerability, Pharmacokinetics, and Efficacy of JMT108 Injection in Participants With Unresectable or Metastatic Melanoma and Urinary Tract Tumors","sponsor":"Shanghai JMT-Bio Inc.","enrolled":500,"outcomes":[]},"route":"/trials/nct07280832/","neighbours":{"cancer":[{"id":"melanoma","kind":"cancer","name":"Melanoma","route":"/cancers/melanoma/"}],"company":[{"id":"cspc","kind":"company","name":"CSPC Pharmaceutical Group","route":"/companies/cspc/"}]}}